Context Therapeutics Inc (CNTX)

$2.88 -0.11 (-3.68%)
Market Cap 268.29M
Revenue (ttm) 0.00
Net Income (ttm) -26.73M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 636,100
Avg Vol 1,524,346
Day's Range N/A - N/A
Shares Out 91.88M
Stochastic %K 19%
Beta 1.96
Analysts Strong Sell
Price Target $5.62

Company Profile

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 201...

Industry: Biotechnology
Sector: Healthcare
Phone: 267 225 7416
Address:
2001 Market Street, Suite 3915 Unit #15, Philadelphia, United States
hugoraciel
hugoraciel Mar. 17 at 8:58 PM
$CNTX 👇 📉 Drop Pulled from 3.60 → ~3.05 Driven by pre-earnings positioning + downgrade pressure  📊 Pattern Flush → bounce (~3.30) → reset Controlled moves, not random 📈 Trend Holding 3.00–3.10 strong Still in accumulation range 📰 News Factor • Earnings coming March 19 → volatility expected  • Mixed sentiment (downgrade vs “moderate buy”)  🔮 Outcome • Hold 3.00 → push 3.30 → 3.60+ • Break 3.60 → opens next leg up 🚀
1 · Reply
LabPsycho
LabPsycho Mar. 17 at 5:53 PM
$CNTX Chart the past ~ 2 weeks looking like a delayed replica by about a week, of exactly what $CCCC did - From ~ $2 to $3.50 then crash 80 cents in a couple of days, all on no significant news. Hmmm?
1 · Reply
SpencerF
SpencerF Mar. 17 at 5:34 PM
$CNTX I think my 5 share wall at $2.73 is working
0 · Reply
CocoT_2022
CocoT_2022 Mar. 17 at 3:17 PM
$CNTX why the drop?
1 · Reply
elmono
elmono Mar. 17 at 2:14 PM
$CNTX failed trade for me …..will revisit 2.4 or lower 🤷‍♂️
0 · Reply
revuelto
revuelto Mar. 16 at 11:31 PM
$CNTX a sharp rerating is likely here✌️👍
0 · Reply
hugoraciel
hugoraciel Mar. 16 at 8:39 PM
$CNTX wtf
0 · Reply
J1476
J1476 Mar. 16 at 5:50 PM
$CNTX premarket gap filled…looking for bounce here into the close
0 · Reply
LabPsycho
LabPsycho Mar. 16 at 1:39 PM
$CNTX And there is your $3.50 predicted below. Step one complete.
1 · Reply
hugoraciel
hugoraciel Mar. 16 at 3:39 AM
$CNTX is it at 3.53?
0 · Reply
Latest News on CNTX
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026

Mar 19, 2026, 7:30 AM EDT - 2 days ago

Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026

Context Therapeutics to Participate in Upcoming Investor Conferences

Feb 9, 2026, 7:30 AM EST - 5 weeks ago

Context Therapeutics to Participate in Upcoming Investor Conferences

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 16, 2026, 4:05 PM EST - 2 months ago

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting

Nov 7, 2025, 7:30 AM EST - 4 months ago

Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting

Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results

Nov 5, 2025, 4:15 PM EST - 4 months ago

Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results

Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer

Oct 28, 2025, 8:00 AM EDT - 5 months ago

Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer

SKYE

Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

Oct 6, 2025, 7:30 AM EDT - 5 months ago

Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Oct 3, 2025, 4:15 PM EDT - 6 months ago

Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results

Aug 6, 2025, 4:11 PM EDT - 8 months ago

Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results

Context Therapeutics: Undervalued Cancer Fighter

Jun 10, 2025, 7:10 AM EDT - 10 months ago

Context Therapeutics: Undervalued Cancer Fighter

Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting

Jun 2, 2025, 7:30 AM EDT - 10 months ago

Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting

Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer

May 29, 2025, 7:30 AM EDT - 10 months ago

Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer

Context Therapeutics Reports First Quarter 2025 Operating and Financial Results

May 7, 2025, 4:09 PM EDT - 11 months ago

Context Therapeutics Reports First Quarter 2025 Operating and Financial Results

Context Therapeutics Announces Chief Medical Officer Transition

May 5, 2025, 4:05 PM EDT - 11 months ago

Context Therapeutics Announces Chief Medical Officer Transition

Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting

Apr 30, 2025, 7:30 AM EDT - 11 months ago

Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting

Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95

Apr 9, 2025, 7:30 AM EDT - 1 year ago

Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95

Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025

Mar 26, 2025, 4:02 PM EDT - 1 year ago

Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025

Context Therapeutics Reports Full Year 2024 Operating and Financial Results

Mar 20, 2025, 4:22 PM EDT - 1 year ago

Context Therapeutics Reports Full Year 2024 Operating and Financial Results

Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76

Jan 14, 2025, 4:58 PM EST - 1 year ago

Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76

Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors

Jan 13, 2025, 7:30 AM EST - 1 year ago

Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors

Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results

Nov 6, 2024, 4:06 PM EST - 1 year ago

Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results

Context Therapeutics to Participate in Upcoming Investor Conferences in November

Oct 23, 2024, 7:30 AM EDT - 1 year ago

Context Therapeutics to Participate in Upcoming Investor Conferences in November

Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Oct 16, 2024, 7:30 AM EDT - 1 year ago

Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors

Sep 4, 2024, 7:30 AM EDT - 1 year ago

Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors

Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results

Aug 7, 2024, 4:17 PM EDT - 1 year ago

Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results

Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations

Aug 1, 2024, 7:30 AM EDT - 1 year ago

Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations

Context Therapeutics: Acquired Asset CT-95 Could Enhance T-Cell Engager Pipeline

Jul 10, 2024, 2:06 PM EDT - 1 year ago

Context Therapeutics: Acquired Asset CT-95 Could Enhance T-Cell Engager Pipeline

Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95

Jul 10, 2024, 7:30 AM EDT - 1 year ago

Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95

Context Therapeutics Reports First Quarter 2024 Operating and Financial Results

May 8, 2024, 4:06 PM EDT - 2 years ago

Context Therapeutics Reports First Quarter 2024 Operating and Financial Results

Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76

May 2, 2024, 7:31 AM EDT - 2 years ago

Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76

Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers

Apr 1, 2024, 7:30 AM EDT - 2 years ago

Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers

Context Therapeutics Reports Full Year 2023 Operating and Financial Results

Mar 21, 2024, 7:43 AM EDT - 2 years ago

Context Therapeutics Reports Full Year 2023 Operating and Financial Results

Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results

Nov 9, 2023, 4:15 PM EST - 2 years ago

Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results

Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Sep 27, 2023, 9:00 AM EDT - 2 years ago

Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results

Aug 9, 2023, 4:10 PM EDT - 2 years ago

Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results

Context Therapeutics to Participate in Two August 2023 Investor Conferences

Aug 1, 2023, 7:30 AM EDT - 2 years ago

Context Therapeutics to Participate in Two August 2023 Investor Conferences

Context Therapeutics Reports First Quarter 2023 Operating and Financial Results

May 10, 2023, 4:39 PM EDT - 3 years ago

Context Therapeutics Reports First Quarter 2023 Operating and Financial Results

Significant Unmet Need In Solid Tumors Reported, And How Context Therapeutics (NASDAQ:CNTX) Plans To Make A Difference

Apr 18, 2023, 10:15 AM EDT - 3 years ago

Significant Unmet Need In Solid Tumors Reported, And How Context Therapeutics (NASDAQ:CNTX) Plans To Make A Difference

Context Therapeutics to Participate in Two April 2023 Investor Conferences

Apr 3, 2023, 7:30 AM EDT - 3 years ago

Context Therapeutics to Participate in Two April 2023 Investor Conferences

Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates

Mar 22, 2023, 5:08 PM EDT - 3 years ago

Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates

Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023

Mar 15, 2023, 7:30 AM EDT - 3 years ago

Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023

Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer

Feb 6, 2023, 7:30 AM EST - 3 years ago

Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer

Context Therapeutics' Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer

Jan 31, 2023, 7:30 AM EST - 3 years ago

Context Therapeutics' Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer

Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers

Jan 9, 2023, 7:30 AM EST - 3 years ago

Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers

Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones

Jan 4, 2023, 7:30 AM EST - 3 years ago

Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones

Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer

Dec 8, 2022, 7:30 AM EST - 3 years ago

Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer

Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors

Nov 29, 2022, 7:30 AM EST - 3 years ago

Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors

Context Therapeutics® Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer Symposium

Nov 21, 2022, 9:11 AM EST - 3 years ago

Context Therapeutics® Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer Symposium

Context Therapeutics® Reports Third Quarter 2022 Operating and Financial Results

Nov 9, 2022, 4:14 PM EST - 3 years ago

Context Therapeutics® Reports Third Quarter 2022 Operating and Financial Results

Context Therapeutics to Participate in the ThinkEquity Conference

Oct 20, 2022, 7:30 AM EDT - 3 years ago

Context Therapeutics to Participate in the ThinkEquity Conference

hugoraciel
hugoraciel Mar. 17 at 8:58 PM
$CNTX 👇 📉 Drop Pulled from 3.60 → ~3.05 Driven by pre-earnings positioning + downgrade pressure  📊 Pattern Flush → bounce (~3.30) → reset Controlled moves, not random 📈 Trend Holding 3.00–3.10 strong Still in accumulation range 📰 News Factor • Earnings coming March 19 → volatility expected  • Mixed sentiment (downgrade vs “moderate buy”)  🔮 Outcome • Hold 3.00 → push 3.30 → 3.60+ • Break 3.60 → opens next leg up 🚀
1 · Reply
LabPsycho
LabPsycho Mar. 17 at 5:53 PM
$CNTX Chart the past ~ 2 weeks looking like a delayed replica by about a week, of exactly what $CCCC did - From ~ $2 to $3.50 then crash 80 cents in a couple of days, all on no significant news. Hmmm?
1 · Reply
SpencerF
SpencerF Mar. 17 at 5:34 PM
$CNTX I think my 5 share wall at $2.73 is working
0 · Reply
CocoT_2022
CocoT_2022 Mar. 17 at 3:17 PM
$CNTX why the drop?
1 · Reply
elmono
elmono Mar. 17 at 2:14 PM
$CNTX failed trade for me …..will revisit 2.4 or lower 🤷‍♂️
0 · Reply
revuelto
revuelto Mar. 16 at 11:31 PM
$CNTX a sharp rerating is likely here✌️👍
0 · Reply
hugoraciel
hugoraciel Mar. 16 at 8:39 PM
$CNTX wtf
0 · Reply
J1476
J1476 Mar. 16 at 5:50 PM
$CNTX premarket gap filled…looking for bounce here into the close
0 · Reply
LabPsycho
LabPsycho Mar. 16 at 1:39 PM
$CNTX And there is your $3.50 predicted below. Step one complete.
1 · Reply
hugoraciel
hugoraciel Mar. 16 at 3:39 AM
$CNTX is it at 3.53?
0 · Reply
J1476
J1476 Mar. 16 at 1:08 AM
$CNTX
0 · Reply
LabPsycho
LabPsycho Mar. 15 at 7:43 PM
$CNTX @J1476 @Doom_Gloom_AR Yes, CNTX surely weathered the (temporary?) storm the past couple weeks. I think $6 is a bit high - their market cap already pretty rich (compared to say CCCC which is at cash and in phase 2 and partnerships) IMO. Unless CTIM76 results are shockingly good. There probably is a reason I spent so much time, research and effort on this one over 2.5 yr ago doing molecular simulations and a video about Claudin 6 - it has a lot of appeal....but AMGN seemed to pause the development of thier Claudin 6 Bite for some reason. Good luck.
0 · Reply
topstockalerts
topstockalerts Mar. 13 at 7:32 PM
$CNTX These lower liquidity setups often stay quiet until a headline sparks interest. Once volume appears the chart can move quickly.
0 · Reply
LabPsycho
LabPsycho Mar. 13 at 7:08 PM
$CNTX Per @Doom_Gloom_AR post, I was in a rush and left out an important catalyst on my speculative future events below. * Phase 1a CTIM-76 data This could come after the IND filing. I also think these two potential announcements could be made only a few days apart. My way of looking at this, if there is a money raise before clinical data, yellow / red flag and retrace. If they wait and data is good and then raise, green flag going higher. All wild guesses of course. I am interested in reading other Posters ideas of what they think may transpire over the next several weeks
1 · Reply
LabPsycho
LabPsycho Mar. 13 at 1:46 PM
$CNTX Here is my wild speculation of potential events before May 31, 2026 * CNTX to $3.50 near term * IND filing - share prices spike higher * Followed shortly thereafter by Private placement and share price drop * Several $$ MILLION payment to BCAB * Somehow I think there is a play / partnership / buyout something else going to happen between beat down BCAB and CNTX , but too complex even for me to speculate * Summer biotech blues - most biotechs getting stale. Wild speculations based on Stage 3 Wealth Transfer Iran war not further escalating.
3 · Reply
stck957
stck957 Mar. 13 at 12:59 PM
$CNTX If it can push through $3.30. Next targets would be. $3.50 $3.75 $4.00
1 · Reply
cyno
cyno Mar. 12 at 7:59 PM
$CNTX when is the earnings on this stock?
0 · Reply
J1476
J1476 Mar. 11 at 9:45 PM
$CNTX
0 · Reply
Doom_Gloom_AR
Doom_Gloom_AR Mar. 11 at 6:49 PM
$CNTX nice little talk at Leerink - TCE are hot - this will zoom to 1b company on decent results. https://event.summitcast.com/view/mT9poctHDNthc6b89WqVjf/XG5T44wDZtFqK3hid5hfLz
0 · Reply
hugoraciel
hugoraciel Mar. 11 at 5:19 PM
$CNTX 5000 watchers n no one says anything on this play
0 · Reply
hugoraciel
hugoraciel Mar. 9 at 10:21 PM
$CNTX and $ARDX ARE GETTING IN MY LAST NERV. takes weeks to move $1 Then 30 seconds to drop $2 Im exaggerating but its like
0 · Reply
hugoraciel
hugoraciel Mar. 9 at 9:22 PM
$CNTX Trend projection: CNTX is moving inside a rising channel. The upper trend-line extension points to $3.40–$3.70, with $3.42 sitting near the center of that path. Time estimate: about 3–4 weeks along the current trend slope.
0 · Reply